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ABSTRACT 
 
Liver disease have protean presentations: acute liver failure, insidious chronic 
liver disease, or an incidental finding of abnormal liver function tests. In this 
article we discuss the identification of liver disease and ‘red flags’ in four specific 
clinical situations: conjugated prolonged jaundice; acute liver failure; new-onset 
jaundice in a teenager; and incidental finding of abnormal aminotransferases. 
These scenarios are used to illustrate how ancillary investigations aid diagnosis. 
INTRODUCTION 
 
Liver disease in children has varied presentation, ranging from the frequently 
encountered prolonged, neonatal jaundice to the comparatively rare acute liver 
failure. Due to the supra-regional specialisation of UK hepatology services, many 
paediatricians may not have extensive clinical exposure to these conditions. This 
article will focus on how blood tests may be interpreted in clinical context to 
identify important liver pathologies.  
 
Liver function tests (LFTs) are among the most frequently performed blood tests 
in children. They are often requested as part of an automated biochemistry panel, 
which results in incidental identification of abnormalities. Whilst they may be 
valuable first-line investigations in the assessment of liver disease, they usually do 
not test the functional capacity of the liver, nor are abnormalities necessarily 
specific for individual liver diseases, though some patterns may be observed. 
 
Due to the liver’s considerable functional reserve, liver disease often remains 
subclinical until relatively advanced[1,2]. Therefore, in addition to patients with 
symptoms or signs of liver disease (e.g. jaundice, splenomegaly), evidence of liver 
(dys)function should be actively sought in certain groups of patients, including: 
hepatotoxic medication (e.g. methotrexate) and systemic conditions that may 
affect the liver (e.g. ulcerative colitis with associated sclerosing cholangitis, or 
obesity and NAFLD). 
 
 
BACKGROUND PATHOPHYSIOLOGY 
 
Appropriate requesting and interpretation of liver function tests requires an 
understanding of hepatobiliary cellular structure, liver physiology, and non-liver 
sources of certain enzymes or proteins measured by LFTs.  
 
Liver microanatomy and physiology 
The functional unit of the liver is the hepatocyte. Plates of hepatocytes comprise 
the hepatic lobule, with portal tracts at the periphery and a central vein in the 
middle (see figure 1.). Arterial and portal venous blood mixes in sinusoids that run 
either side of plates of hepatocytes. Hepatocytes secrete products for excretion 
into bile in canaliculi (formed from the lateral wall of hepatocytes), which drains 
into bile ducts. Cholangiocytes (biliary epithelial cells) line bile ducts and the 
remainder of the biliary system. 
 
<Figure 1> 
 
There are several key functions of the liver, including synthetic, metabolic, 
production of bile, and detoxification. Though variable, end-stage chronic liver 
disease tends to manifest in blood tests as coagulopathy and hypoalbuminaemia, 
whilst acute liver failure results in coagulopathy, hypoglycaemia, and 
hyperbilirubinaemia. The degree of abnormality of INR, albumin, pH, lactate, 
bilirubin, and glucose does correlate with the degree of hepatic dysfunction. 
 
Bilirubin 
Bilirubin is the breakdown product of haem, 95% of which comes from red cell 
haemoglobin. It is produced as unconjugated bilirubin by the reticuloendothelial 
system and transported to hepatocytes, where it is converted to conjugated 
bilirubin before being exported into canaliculi (see figure 2.). 
 
 
<Figure 2> 
 
Serum bilirubin may be measured in total, or split into conjugated and total forms. 
Measurement of direct bilirubin is assumed to be synonymous with conjugated 
bilirubin, however there is a small amount of unconjugated bilirubin unbound to 
albumin (‘free’), which will also react (see figure 3). The greater the total bilirubin, 
the more free unconjugated bilirubin will be present. Therefore, the higher the 
total bilirubin, the more the direct bilirubin will be influenced by unconjugated 
bilirubin[3]. 
 
 
<Figure 3> 
 
Liver enzymes 
The enzymes that comprise the typical biochemical panel of LFT are not only 
expressed in the liver (see table 1). Hence, AST/ALT elevation could be of muscle 
origin and concomitant CK measurement is usually helpful to attribute the 
aminotransferase rise to muscle disease[3]. Mild elevations of ALT and AST occur 
in almost any liver condition, however, the degree of increase in 
aminotransferases does not give useful information about liver function or 
underlying diagnosis. 
 
Table 1. Sources of hepatic enzymes. 
<Table 1> 
 
Enzyme  Source   
Aminotransferases  
AST - Liver, heart, skeletal muscle, kidney, 
pancreas, red cells 
ALT – Liver, skeletal muscle, heart 
ALP  Bone, small intestine, liver, placenta, kidney 
GGT 
Biliary epithelial, hepatocytes, renal tubules, 
pancreas, brain, breast, small intestine  
Typically, ALP and GGT both rise in response to biliary injury (intra- or extra-
hepatic), however ALP correlates with bone turnover in children, therefore GGT 
is used in preference as the main biliary enzyme during childhood. However, both 
normal and elevated GGT levels may be of diagnostic significance, as discussed 
below, particularly in differentiating intrahepatic cholestasis syndromes. 
 
Liver ‘function’ tests 
Hepatocytes synthesise the majority of all serum proteins, including albumin and 
clotting factors. Albumin is used as a medium-term marker of hepatic synthetic 
function[4] whilst INR (international normalised ratio) and PT (prothrombin 
time) can be used as short-term markers of synthetic capacity, if haematological 
causes and vitamin K deficiency have been ruled out. It should be remembered 
that INR was designed for monitoring of warfarin activity however is a useful 
method for standardising prothrombin time between laboratories. 
 
Encephalopathy results from the accumulation of nitrogenous compounds and 
endogenous opioids, therefore elevation of ammonia is used in the diagnosis of 
hepatic encephalopathy. It has a good negative predictive value: hepatic 
encephalopathy is unlikely in the setting of a normal ammonia[5]. Urea cycle 
disorders should also be considered when ammonia level is elevated. 
 
 
CASE 1: 
A 6 week old infant is referred to the paediatric unit due to prolonged jaundice. 
She has pigmented stools, colour confirmed by the treating physician. Blood 
results: total bilirubin 168 mol/L, conjugated bilirubin 140 mol/L, ALT 150 
IU/L, AST 161 IU/L, GGT 30 IU/L, Alb 36 g/L, INR 1.2. 
 
Prolonged, conjugated jaundice 
Prolonged jaundice is defined as visible jaundice at 14 days in term infants or 21 
days in those born at less than 37 weeks. The most common cause for 
unconjugated hyperbilirubinaemia is breastfeeding associated jaundice, which 
may be present in 25-45% of breastfed neonates[6]. Whereas, there is a wide 
differential for conjugated hyperbilirubinaemia (where conjugated bilirubin 
comprises >20% of the total bilirubin or an absolute value of 25 mol/L[7,8], see 
table 2) as the neonatal liver has a tendency to develop cholestasis in response to 
a variety of insults. Initial investigation should focus on: confirming conjugated 
hyperbilirbinaemia, looking for evidence of acute liver failure or sepsis, and then 
investigating the cause (table 2)[8]. Early discussion with a hepatology unit 
facilitates rapid investigation of time-critical diagnoses. 
 
Test  Abnormality  Suggests a diagnosis of 
Viral hepatitis serology 
Positive results on 
serology  
HSV, hepatitis A/B/C 
viruses 
Congenital infection serology 
Positive IgM 
CMV PCR (urine & blood) 
Toxoplasma, rubella, CMV, 
HSV 
Blood & urine culture Bacterial growth Sepsis 
Immunoreactive trypsinogen 
(IRT) – under 2-3 weeks age 
Raised IRT 
Cystic fibrosis 
Sweat test Raised sweat chloride 
Alpha-1-antitrypsin levels and 
Pi type  
PiZZ 
Alpha-1-antitrypsin 
deficiency  
Galactose-1-phosphate uridyl 
transferase 
Low enzymatic activity Galactosaemia 
Thyroid function tests Low T4, high TSH Congenital hypothyroidism 
Plasma amino acids Raised tyrosine 
Tyrosinaemia 
Non specific 
Urine organic acids Raised succinylacetone Tyrosinaemia 
Alpha fetoprotein  Significantly increased* 
Hepatoblastoma, 
tyrosinaemia, or non-
specific 
Ultrasound abdomen 
Absent or abnormal gall 
bladder 
Biliary atresia 
Cyst of common bile duct Choledochal cyst 
Table 2. Initial investigations used in identifying causes of neonatal conjugated 
hyperbilirubinaemia. *Elevated alpha fetoprotein in neonates may be normal. 
CMV – cytomegalovirus; EBV – Epstein-Barr virus; HSV – herpes simplex virus; 
IRT – immunoreactive trypsin; PCR – polymerase chain reaction;  TSH – thyroid-
stimulating hormone 
 
<Table 2> 
 
Differential of conjugated hyperbilirubinaemia 
Biliary atresia is an important cause of neonatal cholestasis, accounting for 25% 
of all neonatal conjugated hyperbilirubinaemia presenting to a tertiary centre, 
and early treatment significantly improves outcomes[9]. It typically presents 
with pale stools (not golden yellow or green; any other colour is compatable with 
diagnosis of biliary atresia ), conjugated hyperbilirubinaemia, aminotransferases 
in the hundreds, and an elevated GGT. Physical inspection of the stool to confirm 
the pigment by healthcare professionals is strongly recommended. 
 
The infant in this vignette has a conjugated hyperbilirubinaemia but her stools 
are pigmented and she has a low GGT. She is not in liver failure (and does not 
have vitamin K deficiency) given her normal INR. The pigmented nature of her 
stools does not exclude cholestasis. However, the low GGT helps to narrow the 
differential diagnosis by favouring progressive familial intrahepatic cholestasis 
(PFIC). This infant will need referral to a liver centre for further management. 
 
PFIC is a group of rare conditions caused by germline mutation of canalicular 
membrane transporters. PFIC type 1 may be associated with short stature, short 
digits, and diarrhoea. Bile Salt Export Protein (BSEP) deficiency (PFIC type 2) has 
no additional extra-hepatic phenotype. Though variable, the natural history of 
low GGT intrahepatic cholestasis is unremitting progression with end-stage liver 
in early childhood 
 
CASE 2: 
A 5 year old presents to A&E with sudden onset jaundice and malaise. Blood 
results: total bilirubin 190 mol/L, conjugated bilirubin 170 mol/L, ALT 850 
IU/L, AST 800 IU/L, GGT 110 IU/L, Alb 35 g/L, INR 3.1. Repeat INR 4-hours after 
2mg IV vitamin K is 3.0. 
 
Acute liver failure 
This girl has presented with acute liver failure (ALF), as identified by 
coagulopathy (INR >2.0) that is unresponsive to vitamin K associated with 
biochemical evidence of hepatocellular injury. An INR >1.5 with evidence of 
encephalopathy would also be classed as ALF. This is a medical emergency; any 
child with an abnormal INR and suspected ALF should be referred to a 
hepatology transplant unit urgently. The differential diagnosis of ALF includes: 
infectious causes, metabolic causes, drugs & toxins (paracetamol overdose), 
rarities, and indeterminate (non-A-E hepatitis). Initial investigations are listed in 
table 3[10]. 
 
Test  Abnormality  Suggests a diagnosis of 
Viral hepatitis serology IgM serology positive 
Hepatitis A,B, & E, CMV, 
EBV, adenovirus, 
enterovirus 
Serum caeruloplasmin Low levels  
Wilson disease  
Serum copper Elevated 
Haemoglobin and 
reticulocytes  
Normocytic anaemia and 
raised reticulocytes 
Direct Coombs’ test Negative 
Urinary copper (pre-/post-
penicillamine challenge) 
Elevated urinary copper 
Autoantibodies  
Positive ANA / ASMA / 
LKM / SLA / LC1 Autoimmune hepatitis 
Immunoglobulins Increased IgG 
Toxicology screen Raised paracetamol level Paracetamol overdose 
Blood gas, serum amino acids, 
urinary organic acids, lactate, 
acyl carnitines, ammonia, 
mitochondrial DNA 
Significant abnormalities 
Metabolic diseases, 
including: mitochondrial, 
fatty acid oxidation defects, 
organic acidaemias, urea 
cycle defects 
Table 3. Examples of initial blood investigations used in identifying the cause of 
acute liver failure. ASMA – anti-smooth muscle antibody; ANA – antinuclear 
antibody; EBV – Esptein-Barr virus; LKM – anti-liver-kidney microsomal 
antibodies; SLA – soluble liver antigen; LC1 – Liver cytosol 1 antigen. 
 
<Table 3> 
 
If there is no history of drug or toxin exposure, then the most likely causes are 
viral or metabolic. Viral causes include hepatitis A & E viruses (usually with 
history of travel to Asia or Africa). Cytomegalovirus, Epstein-Barr virus, and 
herpes simplex virus can cause ALF in immunocompromised patients. 
 
Acute liver failure in infancy is more frequently due to metabolic disorders, 
including galactosaemia and tyrosinaemia. However, at 5 years old, Wilson 
disease may present acutely with Coombs’ negative haemolysis, acute liver failure, 
and renal impairment. 
 
Prognostic markers in ALF 
Early identification of children who will not survive with their native liver allows 
more rapid listing for transplant. The prognostic markers for poor outcome with 
ALF secondary to paracetamol overdose are different to those for ALF due to other 
causes. In non-paracetamol ALF an INR >4 alone would be a poor prognostic 
marker, whereas in paracetamol-induced ALF, acidosis, renal impairment, raised 
lactate, and encephalopathy are more important. There is no correlation between 
ALT and outcome in all cases of ALF. 
 
 
 
 
CASE 3: 
A 13 year old girl presents with jaundice after generally feeling unwell for 1 
month. Blood results: total bilirubin 96 mol/L, conjugated bilirubin 80 mol/L, 
ALT 300 IU/L, AST 290 IU/L, GGT 106 IU/L, Alb 18 g/L, total protein 40 g/L, INR 
2.5, platelets 113x109/L. 4 hours after 10mg IV phytomenadione, INR 1.1. 
Urinary copper 0.4 mol/24-hours, serum caeruloplasmin 0.5 g/L. 
 
Acute hepatic dysfunction, without liver failure 
This teenager has presented with a short history of new-onset conjugated 
jaundice associated with elevated aminotransferases. She is not in acute liver 
failure as her INR normalised following vitamin K administration, suggesting 
vitamin K deficiency, which may be due to inadequate bile acid delivery to the 
gut. This is an acute-on-chronic presentation, as evidence by low albumin, and 
thrombocytopenia due to hypersplenism from portal hypertension. 
 
The main differential diagnosis is between autoimmune hepatitis and Wilson 
disease. The initial investigations above point towards autoimmune hepatitis due 
to low albumin and elevated immunoglobulins. Infection should also be 
considered as a cause for raised IgG. The normal caeruloplasmin and 24-hour 
urinary copper make Wilson disease unlikely. 
 
Autoimmune hepatitis 
Autoimmune hepatitis (AIH) is a rare condition of hepatic inflammation 
associated with circulating non-organ specific autoantibodies[11]. It 
demonstrates a good response to immunosuppression, which greatly improves 
the clinical outcome for affected children. There are three types of AIH, based upon 
the autoantibodies present (see table 4), though they have a similar clinical 
course. 
 
The two most discriminatory laboratory investigations are immunoglobulin G 
(IgG) titre and high-titre non-organ-specific autoantibodies[11]. IgG is raised in 
85-90% of all patients with AIH. 
 
Table 4. Differences of type 1, 2, and 3 autoimmune hepatitis[12]. SMA – smooth 
muscle antibody; ANA – antinuclear antibody; LC1 – liver cytosol 1; LKM – Liver-
kidney microsomal antigen; LP – liver-pancreas; pANCA – perinulcear anti-
neutrophil cytoplasmic antibodies; SLA – soluble liver antigens 
 
<Table 4> 
 
Wilson disease 
 Type I Type II Type III 
Antibodies  Anti-SMA, ANA, 
pANCA 
Anti-LKM1 /-LC1 Anti-LC/-SLA 
Age  Peak at 10-20 and 
45-70 years 
2-14 years Peak at 10-20 
and 45-70 
years 
Increased IgG ↑↑↑ ↑ ↑↑ 
Associations HLA B8, DR3, DR4 HLA DR7, DR3   
Other features needed to exclude an alternative diagnosis are a negative viral 
hepatitis screen and exclusion of Wilson disease (WD). Ruling out WD is 
challenging, though patients with WD may have higher bilirubin, ALT/AST in low 
hundreds, and low ALP. Caeruloplasmin is low in the majority of affected patients. 
It is not 100% sensitive (see table 5) [13] but it is the authors’ clinical experience 
that most patients have caeruloplasmin <0.05g/L. Urinary copper should be high 
(with further elevation after penicillamine) but definitive diagnosis of WD needs 
genetics (for ATP7B mutation) or liver copper measurement. 
 
 
 
Caeruloplasmin 
concentration 
cut-off (g/L) 
Sensitivity 
(%) 
Specificity 
(%) 
Positive 
predictive 
value (%) 
Negative 
predictive 
value (%) 
0.20 98 56 48 99 
0.14 93 100 100 97 
0.10 79 100 100 92 
Table 5[13]. Data on the validity of use of 3 different cut-off thresholds of 
caeruloplasmin for diagnosis of Wilson disease in patients clinically suspected of 
having the condition. 
 
<Table 5> 
 
Patients with features suggestive of AIH should be referred to a tertiary liver 
centre, where a liver biopsy may be performed to confirm the diagnosis prior to 
starting treatment. 
 
 
------------------------------------------------------------------------------------------------------ 
BOX 2. ‘Dos and Don’ts’ in suspected liver disease 
 
Dos 
- Check the prothrombin time (or INR) 
- Discuss early with a hepatology centre 
- Closely monitor  liver function tests while awaiting a formal plan of 
management  
 
Don’ts 
- Use ALT or AST as a marker of hepatic function or severity of disease 
- Ignore unexplained abnormal LFTs, even in clinically well children 
- Assume a diagnosis without completing investigations (e.g. diagnosing 
NAFLD without fully excluding Wilson disease) 
------------------------------------------------------------------------------------------------------ 
  
CASE 4: 
A 15 year old is seen by the paediatric surgical team with vague abdominal pain. 
BMI 32.9 kg/m2, BMI z-score +2.29, waist circumference 99th centile. Blood 
results: total bilirubin 13 mol/L, ALT 110 IU/L, AST 101 IU/L, GGT 65 IU/L, Alb 
35 g/L, INR 1.0. 
 
Non-alcoholic fatty liver disease 
This 15 year old has had incidental abnormalities LFT identified for which the 
most likely diagnosis is non-alcoholic fatty liver disease (NAFLD). 
 
A careful history and examination should be undertaken for features of AIH, 
Wilson disease, and inborn errors of metabolism, as discussed above. An 
ultrasound demonstrating increased hepatic echogenicity (suggestive of fat 
infiltration), with a negative panel of secondary investigations (see table 6), and 
no history of alcohol intake would suggest a diagnosis of NAFLD in the context of 
an obese child, but specialist opinion is advised. Diagnosis can only formally be 
made by liver biopsy, which is also useful for staging disease. 
 
Test  Abnormality  Suggests a diagnosis of 
Viral hepatitis serology 
IgG or IgM serology 
positive 
Hepatitis B & C, EBV, CMV 
Serum caeruloplasmin Low levels  
Wilson disease  
Urinary copper 
Elevated 24-hour 
excretion 
Autoantibodies  
Positive ANA / ASMA / 
LKM / SLA / LC1 Autoimmune hepatitis 
Immunoglobulins Increased IgG 
Alpha-1-antitrypsin levels and 
Pi type  
PiZZ 
Alpha-1-antitrypsin 
deficiency  
Oral glucose tolerance test 
Raised fasting insulin, or 
impaired glucose 
tolerance 
Insulin resistance 
High-density lipoprotein 
(HDL), low-density 
lipoprotein (LDL), 
triglycerides (TG) 
Low HDL, high LDL, high 
TG 
Dyslipidaemia or lysosomal 
acid lipase disease  
Table 6. Ancillary investigations used in excluding secondary causes of hepatic 
steatosis and to look for end-organ damage in NAFLD. ASMA – anti-smooth 
muscle antibody; ANA – antinuclear antibody; CMV – cytomegalovirus; EBV – 
Esptein-Barr virus; LKM – anti-liver-kidney microsomal antibodies; SLA – 
soluble liver antigen; LC1 – Liver cytosol 1 antigen. 
 
<Table 6> 
 
Non-alcoholic fatty liver disease (NAFLD) describes a spectrum from isolated 
hepatic steatosis through non-alcoholic steatohepatitis (NASH) to fibrosis, 
ultimately leading to cirrhosis[14]. The condition is intimately related to obesity, 
insulin resistance, and the metabolic syndrome. Approximately 40% of obese 
children are affected with NAFLD[15]. Up to 9% of children with only ‘mildly’ 
abnormal LFT can have stage 3/4 fibrosis on biopsy[16] and 25% of those with 
stage 3/4 fibrosis have normal AST/ALT. There is no correlation between ALT and 
fibrosis; and fibrosis is the best marker of long-term outcome in adults[17]. This 
statement is true for many chronic liver diseases: normal AST and ALT give little 
information about progression of the condition. 
 
Management of NAFLD 
Long-term, patients with NAFLD are at increased risk of all complications of the 
metabolic syndrome, therefore children should be managed in accordance with 
guidance from the RCPCH Obesity Serivces for Children and Adolescents 
group[18].  
 
There are no uniformally accepted pharmacological therapies recommended for 
paediatric NAFLD other than weight loss and exercise. Some suggested situations 
for when to refer to tertiary hepatology services are listed in Box 1[19]. 
 
------------------------------------------------------------------------------------------------------ 
BOX 3. When to refer children with suspected non-alcoholic fatty liver 
disease 
- Diagnostic uncertainty 
- Non-obese 
- ALT or AST >1.5x upper limit of normal 
- Splenomegaly 
- Under 8 years of age 
- Evidence of hepatocellular dysfunction or portal hypertension 
- Persistently raised aminotransferases or gamma glutamyl transferase 
despite 3 months of lifestyle modification 
------------------------------------------------------------------------------------------------------ 
 
 
------------------------------------------------------------------------------------------------------ 
BOX 1. ‘Red flags’ in suspected liver disease 
- Any encephalopathy 
- INR >1.5, which does not normalise with IV vitamin K 
- pH <7.3 
- Hypoglycaemia 
- High or rising lactate 
- High or rising creatinine or other evidence of renal dysfunction  
- Evidence of hepatocellular dysfunction (low albumin, hypoglycaemia) 
- Evidence of portal hypertension (splenomegaly, thrombocytopenia) 
------------------------------------------------------------------------------------------------------ 
 
 
CONCLUSIONS 
ALT/AST, bilirubin, and GGT should be thought of as a screen for acute hepato-
biliary injury, though may be normal despite chronic liver disease. Whereas 
coagulation, glucose, albumin, and pH are more informative of physiological 
capacity. Diagnosis of specific pathologies requires an additional set of 
investigations with correlation to the clinical signs and symptoms of the patient. 
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FIGURE LEGENDS 
 
Figure 1. Six portal triads are arranged around a central vein in the classical 
hepatic lobule. A hepatic acinus illustrates the direction of blood flow. The 
zoomed image shows plates of hepatocytes lining a sinusoid. Bile drains in 
canaliculi in the opposite direction to blood flow, back towards the portal triad. 
 
Figure 2. Measurement of direct conjugated and total bilirubin. Sodium benzoate 
is added to free bound unconjugated bilirubin in measurement of total bilirubin. 
Direct bilirubin predominantly reflects conjugated bilirubin however a 
proportion of unconjugated bilirubin is unbound, which will influence the result. 
 
Figure 2. Bilirubin metabolism with the site pre-, intra-, and post-hepatic 
jaundice illustrated. 
 
